title: Reducing elevated plasma LDL cholesterol: the central role of the LDL receptor.
abstract: Elevated low-density lipoprotein cholesterol (LDL-C) is an established risk factor for cardiovascular disease (CVD), and reduction of elevated LDL-C reduces mortality in patients at risk. This benefit has evolved from the use of statins and knowledge of the LDL receptor (LDLR). The most potent drugs used for dyslipidemias act by mechanisms that involve this receptor. Advances in molecular genetics and understanding of the regulation of this receptor have revealed several pharmacological targets that are being explored to develop more targeted therapies for dyslipidemias.
authors.affiliation: Pfizer Global Pharmaceuticals, New York, New York, USA.
authors.forename: J
authors.initials: J
authors.lastname: Vincent
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000097:blood*; D050171:Dyslipidemias / Q000188:drug therapy*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D011973:Receptors, LDL / Q000378:metabolism*
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D011973:Receptors, LDL